JAK1/JAK2 inhibition by baricitinib in diabetic kidney disease: results from a Phase 2 randomized controlled clinical trial

BACKGROUND: Inflammation signaled by Janus kinases (JAKs) promotes progression of diabetic kidney disease (DKD). Baricitinib is an oral, reversible, selective inhibitor of JAK1 and JAK2. This study tested the efficacy of baricitinib versus placebo on albuminuria in adults with Type 2 diabetes at hig...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Nephrol Dial Transplant
Autors principals: Tuttle, Katherine R, Brosius, Frank C, Adler, Sharon G, Kretzler, Matthias, Mehta, Ravindra L, Tumlin, James A, Tanaka, Yoshiya, Haneda, Masakazu, Liu, Jiajun, Silk, Maria E, Cardillo, Tracy E, Duffin, Kevin L, Haas, Joseph V, Macias, William L, Nunes, Fabio P, Janes, Jonathan M
Format: Artigo
Idioma:Inglês
Publicat: Oxford University Press 2018
Matèries:
ORIGINAL ARTICLES
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6212720/
https://ncbi.nlm.nih.gov/pubmed/29481660
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ndt/gfx377
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars